002365SZSE

2025 Annual Audit Report

✨ AI Summary

This document presents the 2025 annual audit report and financial statements for Qianjiang Yong'an Pharmaceutical Co., Ltd. The report includes the auditor's opinion, key audit matters, and detailed financial statements such as the balance sheet, income statement, cash flow statement, and statement of changes in owners' equity for both consolidated and parent company figures. It confirms the financial statements comply with accounting standards and provide a fair representation of the company's financial position and performance.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_documentSign In to Upgrade

Qianjiang Yong'an Pharmaceutical Co., Ltd. Audit Report and Financial Statements For the Year Ended December 31, 2025

Table of Contents

Audit Report 1-5 II. Financial Statements Consolidated Balance Sheet and Parent Company Balance Sheet 1-4 Consolidated Income Statement and Parent Company Income Statement 5-6 Consolidated Cash Flow Statement and Parent Company Cash Flow Statement 7-8 Consolidated Statement of Changes in Owners' Equity and Parent Company Statement of Changes in Owners' Equity 9-12 Notes to Financial Statements 1-106

IBDO BDO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP

Audit Report

Audit Firm Report [2026] No. ZE10121

To the Shareholders of Qianjiang Yong'an Pharmaceutical Co., Ltd.:

I. Audit Opinion

We have audited the financial statements of Qianjiang Yong'an Pharmaceutical Co., Ltd. (hereinafter referred to as "Yong'an Pharmaceutical"), which comprise the consolidated and parent company balance sheets as of December 31, 2025, the consolidated and parent company income statements, consolidated and parent company cash flow statements, consolidated and parent company statements of changes in owners' equity for the year then ended, and notes to the financial statements.

In our opinion, the accompanying financial statements, in all material respects, are prepared in accordance with the requirements of the Accounting Standards for Business Enterprises, and fairly present the consolidated and parent company financial position of Yong'an Pharmaceutical as of December 31, 2025, and the consolidated and parent company results of operations and cash flows for the year then ended.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.